A Single-center, Open-label Study to Investigate the Effect of a Single Oral Dose and Repeated Oral Doses of ID-082 on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxymidazolam in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs ID-082 (Primary)
- Indications Unspecified
- Focus Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 11 Jan 2018 Status changed from recruiting to completed.
- 12 Dec 2017 New trial record